Sai Life Sciences has entered a 5five-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the SaiSchrödinger Research Laboratories (SSRL) in Hyderabad

Being built inside Sai Life Sciences' R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal and synthetic chemistry, in vitro biology, and process chemistry. It will access other Sai capabilities such as in vitro ADME and in vivo PK as needed. The relationship will support the advancement of programmes that leverage Schrödinger's validated computational platform

Krishna Kanumuri, CEO and MD, Sai Life Sciences, said, "We're truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set up their first offshore research laboratories. In many ways, this is a testimony to the advances we have made in the scale, scope and depth of our integrated drug discovery capabilities. We are very excited about working with the Schrödinger team and, guided by our brand promise, will strive to make it better together."

Scheduled to open in April 2023, SSRL will commence with about 75 staff members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry, Analytical Chemistry, and other support staff.